Homepage Banner
Home Page Banner
Homepage Banner

Welcome to the 6th Annual RAS-Targeted Drug Development Summit

Uniting Large Pharma, Innovative Biotech & Leading Academics to Defeat the Holy Grail Target in Precision Oncology

With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance. However, treating patients with RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the depth and durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.

Owing to this, the 6th Annual RAS-Targeted Drug Development Summit returns as the central hub dedicated to every aspect of discovery and development of RAS, from discovery and clinical development through to commercialization, equipping 200+ global RAS leaders with the means to create effective frontline RAS therapies for better patient outcomes.

Screenshot 2024-07-01 083513

How Can We Help?

paper-plane-thin-line-icon-airplane-jet-fly-vector-29676044

Got Questions about event details? We are here to help. We can discuss talk timings, answer poster session queries and workshop FAQ's all to ensure your time at the summit is as seamless as possible. Get in touch and we will be happy to help.

What’s New for 2024?

Icon 2

Extensive technical content covering the latest advancements in identifying, validating and clinically progressing pan-RAS and selective inhibitors, vertical and parallel pathway targeting small molecules, cancer vaccines and cell therapies with improved potency and selectivity.

Icon 3

A new cohort of expert speakers and organizations presenting from the likes of Genfleet Therapeutics, Inspirna, Anocca, Bayer, Elicio Therapeutics, Frontier Medicines, Ranok Therapeutics, Ipsen Pharma and more.

Icon 1

Expert-led pre-conference workshops delving into the hottest aspirations of the precision oncology community, including the debate surrounding targeting wildtype RAS, how to overcome acquired resistance and how to inform combinations regimes in and before the clinic.

Latest News Showcased at this Years Summit

Industry News Banner
Industry News Banner
Industry News Banner
Industry News Banner

With updates in the RAS-Targeted Drug Development Space happening fast in the race for first and best in class, see latest updates here and explore the topics these pioneering companies will be discussing in our 2024 full event guide.

2024 Expert Speakers Include:

Andreas Weiss

Andreas Weiss

Associate Director

Norvartis

Kevin Webster

Kevin Webster

Chief Scientific Officer

Frontier Medicines

Qiang Lu

Qiang Lu

Co-Founder & Chairman

GenFleet Therapeutics

Peter DeMuth

Peter DeMuth

Chief Scientific Officer

Elicio Therapeutics

Jan Smith

Jan smith

Chief Scientific Officer

Revolution Medicines

Bhakti Mehta

Bhakti Mehta

Executive Medical Director

Amgen

Geoff Oxnard

Geoff Oxnard

Vice President, Clinical Development, Global Head, Thoracic Cancer

Loxo@Lilly

Ahmadur Rahman

Ahmadur Rahman

Senior Clinical Director & Clinical Science Lead, Global Oncology Research & Development

Roche

A Snapshot of 2023 Attendees

Logo Group

Our 2024 Partners:

Our 2024 Poster Session

Poster Session Image

Our poster sessions are a valuable opportunity to interact and exchange new information with your peers. A poster is a great way to showcase your work, generate discussion, spart an interesting debate and bring awareness to important issues within the industry.

Hear What Our Past Attendees Have to Say:

Background Image

“The summit provides an unparalleled platform to discuss the latest breakthroughs in RAS research and clinical development, making it a valuable resource for anyone seeking to stay up-to-date on this critical area of oncology ”

- Lifecyle Leader, KRAS, Roche

Background Image

"This conference is an exciting and unique opportunity to learn about the latest advancements in RAS research and clinical developments”

- Director, Clinical Biomarkers & Diagnostics, Amgen

Background Image

The 5th RAS Targeted DD Summit brings experts from both academia and industry together to exchange learnings and further brainstorm on how to tackle this important oncogene - Saskia Brachmann, Associate Director &
Senior Global Project Lead, Novartis

- Associate Director & Senior Global Project Lead, Novartis

Background Image

"The 5th RAS Targeted DD Summit is an extraordinary event to strengthen a trusted network of experts in the field of RAS both from academia and industry”

- Associate Professor of Molecular Biology, University of Torino

Other Events in the Series